We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Niraparib Nearly Quadruples Survival Time in BRCA-Mutated Ovarian Cancer
Niraparib Nearly Quadruples Survival Time in BRCA-Mutated Ovarian Cancer
Niraparib almost quadrupled progression-free survival in certain ovarian cancer patients compared to placebo, according to results from a Phase III trial.